MannKind Corp (NASDAQ:MNKD) shares slumped 9% after the therapeutic diabetes products maker said the Food and Drug Administration had extended a review of its insulin drug, Afrezza. The Prescription Drug User Fee Act will expire on July 15. An FDA panel backed the drug last week, sending shares soaring. MannKind Corporation (NASDAQ:MNKD) shares after opening at $6.12 moved to $6.44 on last trade day and at the end of the day closed at $6.32. Company price to cash ratio in past twelve months was calculated as 33.67. MannKind Corporation (NASDAQ:MNKD) showed a positive weekly performance of 57.21%.
The Shareholders Foundation, Inc. announces that a lawsuit was filed on behalf of certain purchasers of SolarCity Corp (NASDAQ:SCTY) common stock over alleged violations of Federal Securities Laws by SolarCity Corp in connection with certain allegedly false and misleading statements. SolarCity Corp (NASDAQ:SCTY) shares fell -8.09% in last trading session and ended the day on $54.30. SCTY return on equity ratio is recorded as -17.30% and its return on assets is -2.80%. SolarCity Corp (NASDAQ:SCTY) yearly performance is 186.24%.
Canadian Solar Inc, (NASDAQ:CSIQ) one of the world’s largest solar power companies, has confirmed that it has been awarded a module supply agreement to provide 18MW of photovoltaic modules for Hitachi Ltd for a solar power project in Japan. Canadian Solar Inc. (NASDAQ:CSIQ) shares moved down -8.49% in last trading session and was closed at $28.35 while trading in range of $27.83 – $31.10 – Canadian Solar Inc. (NASDAQ:CSIQ) year to date (YTD) performance is -4.93%.
VIVUS (NASDAQ:VVUS) was downgraded by equities researchers at Piper Jaffray from a “neutral” rating to an “underweight” rating in a research report issued on Thursday,TheFlyOnTheWall.com reports. VIVUS, Inc. (NASDAQ:VVUS) weekly performance is -14.31%. On last trading day company shares ended up $5.09. VIVUS, Inc. (NASDAQ:VVUS) distance from 50-day simple moving average (SMA50) is -20.64%. Analysts mean target price for the company is $8.50.
Leave a Reply